Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients

OBJECTIVES: Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site‐limited. Liquid biopsy represents a minimal...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Eur J Haematol
Auteurs principaux: Vrabel, David, Sedlarikova, Lenka, Besse, Lenka, Rihova, Lucie, Bezdekova, Renata, Almasi, Martina, Kubaczkova, Veronika, Brožová, Lucie, Jarkovsky, Jiri, Plonkova, Hana, Jelinek, Tomas, Sandecka, Viera, Stork, Martin, Pour, Ludek, Sevcikova, Sabina, Hajek, Roman
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065130/
https://ncbi.nlm.nih.gov/pubmed/31763708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13358
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires